TriviumVet

What TriviumVet does

TriviumVet Designated Activity Company is an animal therapeutics company founded in 2015 and headquartered in Waterford, Ireland, developing first-in-class small-molecule pharmaceuticals for companion animals (cats and dogs). The company's core technology is an mTOR inhibition platform built on sirolimus (rapamycin) in proprietary delayed-release tablet formulations engineered for species-specific pharmacokinetics, supplemented by reformulations of pregabalin and omeprazole for canine indications. Its commercial portfolio includes Felycin-CA1, the first FDA conditionally approved treatment for feline hypertrophic cardiomyopathy; Liavium-CA1, the first FDA conditionally approved pregabalin for canine neuropathic pain associated with Chiari-like malformation and syringomyelia; and Zetbelis, the first veterinary-registered proton pump inhibitor for canine gastric ulceration, which received a positive EMA CVMP opinion.

The business model is pharmaceutical product sales through veterinary prescription channels. TriviumVet develops and licenses formulations and pursues regulatory approvals, with commercialization executed through distribution partners. In May 2025, the company was acquired by U.S.-based PBI-Gordon Corporation, and its products are now commercialized in the US through Pegasus Laboratories under the PRN Pharmacal brand, with EU/UK distribution for Zetbelis also established. The go-to-market motion combines enterprise field sales to specialist veterinary neurology centers, cardiology referral hospitals, and specialty practices with event-driven presence at major veterinary conferences (ACVIM Forum, VMX, WVC, FelineVMA). Clinical evidence is generated through an extensive university research network spanning UC Davis, NC State, Ohio State, Texas A&M, and the Dog Aging Project.

Customer segments are pet owners whose animals suffer from chronic conditions (feline HCM, feline CKD, canine neuropathic pain, canine gastric ulceration) and the specialty veterinarians who prescribe to them. End-customer demand is fragmented across millions of households in the US and EU, but commercial revenue is concentrated through the Pegasus Labs distribution partnership. Following the PBI-Gordon acquisition, TriviumVet operates as an R&D center of excellence within the PBI-Gordon group, advancing a pipeline that includes TRIV307 (feline CKD), TRIV202 (canine cardiomyopathy/age-related decline), TRIV201 (canine neuropathic pain), and TRIV209 (canine PPI).

Name

TriviumVet

Legal name

TriviumVet Designated Activity Company

Website

https://triviumvet.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

1–10 employees

Short description

TriviumVet is an Irish veterinary pharmaceutical company developing first-in-class therapeutics for companion animals, including FDA-approved Felycin-CA1 for feline HCM and Liavium-CA1 for canine neuropathic pain, now operating as an R&D subsidiary of PBI-Gordon Corporation with US commercialization through Pegasus Laboratories.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Companion Animal Therapeutics (Rx) (HLAMAEAA)

akta.pro secondary industries

Oncology & Specialty Therapeutics (HLAMAEAJ), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

Keywords

• Veterinary pharmaceuticals
• Companion animal therapeutics
• Animal drug development
• Feline cardiology drugs
• Veterinary drug pipeline

Headquarters

HQ city

Waterford

HQ country

Ireland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: TriviumVet develops and commercializes novel veterinary pharmaceutical products for companion animals. Following acquisition by PBI-Gordon in 2025, products are commercialized through Pegasus Laboratories in the US market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

TriviumVet is a veterinary pharmaceutical company that develops and commercializes novel therapeutics for chronic diseases in companion animals (cats and dogs). Its portfolio targets conditions with no prior approved treatments — including feline hypertrophic cardiomyopathy (Felycin-CA1), canine neuropathic pain from Chiari-like malformation and syringomyelia (Liavium-CA1), and NSAID-induced gastric ulceration in dogs (Zetbelis/Omeprazole). The company also advances a pipeline of mTOR inhibition-based candidates for canine cardiomyopathy, age-related decline, and feline chronic kidney disease, and operates an R&D center of excellence in Waterford, Ireland, following its 2025 acquisition by PBI-Gordon Corporation.

Product overview

TriviumVet is an innovative animal health company developing first-in-class therapeutics for companion animals across five therapeutic areas: cardiology, gastroenterology, chronic kidney disease, pain management, and age-related decline. The portfolio includes three approved/approvable products: Felycin-CA1 (feline HCM, FDA conditionally approved), Liavium-CA1 (canine neuropathic pain, FDA conditionally approved), and Zetbelis/Omeprazole (canine gastric ulcers, EMA positive opinion). Pipeline candidates include TRIV202 (mTOR platform for canine cardiomyopathy/age-related decline), TRIV201 (canine neuropathic pain), TRIV209 (canine PPI), and TRIV307 (feline CKD). The company was acquired by PBI-Gordon Corporation in 2025 with products commercialized through Pegasus Laboratories.

Differentiator

Problem solved

Functional benefit

Products and services

• Felycin-CA1 Sirolimus delayed release tablets administered once weekly for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). First FDA conditionally approved drug for feline HCM in the US.
• Liavium-CA1 Pregabalin beef-flavored chewable tablets (30mg, 90mg, 180mg strengths) for management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. First FDA conditionally approved pregabalin for veterinary use.
• Zetbelis (Omeprazole TriviumVet) Veterinary proton pump inhibitor (PPI) gastro-resistant capsule for the treatment of NSAID-induced gastric ulceration in dogs. World's first veterinary-registered PPI for canine gastric ulceration; received positive EMA CVMP opinion and is approved in EU and UK markets.
• TRIV202 mTOR inhibition platform under development to treat chronic conditions in dogs and cats, including canine cardiomyopathy and age-related decline in dogs and cats.
• TRIV201 Novel beef-flavored pain management product in development for canine neuropathic pain resulting from diseases or injuries affecting the spinal cord or nerves.
• TRIV209 Veterinary proton pump inhibitor under development for the treatment of gastric ulceration in dogs.
• TRIV307 mTOR inhibition platform under development for the treatment of Chronic Kidney Disease in cats. Eligible for the FDA Expanded Conditional Approval pathway.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Pegasus LaboratoriescoreChannel Partner/ Reseller/ Distributor · 6 May 2025As part of the PBI-Gordon acquisition, TriviumVet's portfolio is commercialized in partnership with Pegasus Laboratories, a leading veterinary pharmaceutical company and part of the PBI-Gordon group. Pegasus distributes products in the US under its PRN Pharmacal brand.
• Dog Aging ProjectcoreStrategic or Co-development PartnerTriviumVet entered a research collaboration with the Dog Aging Project for the TRIAD Trial, a double-blind, placebo-controlled clinical trial of rapamycin to explore its potential to improve health span in dogs. TriviumVet provides its novel veterinary Rapamycin formulation for the trial.
• Texas A&M UniversitycoreStrategic or Co-development PartnerTriviumVet collaborates with Texas A&M University College of Veterinary Medicine & Biomedical Sciences on the REPAIR Study (Rapamycin Treatment in Preclinical Canine Dilated Cardiomyopathy), investigating rapamycin in dogs with preclinical DCM.
• The Ohio State UniversitycoreStrategic or Co-development PartnerTriviumVet works with Dr. Jessica Quimby at The Ohio State University on clinical trials evaluating the effects of their proprietary feline rapamycin formulation in cats with Chronic Kidney Disease (CKD) through the REVERSE Study.
• North Carolina State University (NCSU)coreStrategic or Co-development PartnerPartnership with NC State College of Veterinary Medicine on multiple clinical trials including the RAPACAT HCM study and CHASE Study for canine neuropathic pain. Dr. Kate Meurs serves as Dean and has collaborated on feline HCM research.
• University of California, Davis (UC Davis)coreStrategic or Co-development PartnerTriviumVet partners with UC Davis School of Veterinary Medicine on the RAPACAT HCM clinical trial and other cardiac research projects. Dr. Joshua Stern serves as lead investigator and has been appointed to TriviumVet's Scientific Advisory Board.
• Morris Animal FoundationminorStrategic or Co-development PartnerTriviumVet supports UC Davis and the Morris Animal Foundation in research investigating whether rapamycin can reduce life-threatening heart remodelling associated with subvalvular aortic stenosis (SAS) in dogs.
• Helen RyanminorOthersHelen Ryan appointed as Chairperson of the TriviumVet board. She brings over 25 years of experience in the medical device industry, including as CEO of Creganna Medical which grew five-fold under her leadership.
• Dr. Joshua SternminorOthersDr. Joshua Stern, Professor of Cardiology and Associate Dean at UC Davis, appointed to TriviumVet's Scientific Advisory Board. He is a world leader in translational cardiology and cardiovascular genetic research.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Dechra Pharmaceuticals: UK-headquartered specialty veterinary pharmaceutical company focused on companion animal therapeutics, including novel therapeutics for chronic conditions. Acquired by Eli Lilly in 2024 for approximately $8.6B, Dechra is the closest comparable to TriviumVet in business model, product positioning (specialty vet pharma with first-in-class products), and target market (companion animals).
• Vetoquinol: Independent French veterinary pharmaceutical company with global presence, focused on companion animal and livestock health. Comparable to TriviumVet as a specialty vet pharma player with novel therapeutics, though Vetoquinol has a more diversified portfolio and broader geographic footprint.
• Virbac: Independent global veterinary pharmaceutical company headquartered in France, focused exclusively on animal health. Virbac is comparable to TriviumVet as a specialty vet pharma company with strong companion animal focus, though with significantly larger scale and broader therapeutic area coverage.
• Ceva Santé Animale: French multinational veterinary pharmaceutical company specializing in companion animal and livestock health products. Comparable to TriviumVet in targeting unmet needs in animal therapeutics, with a portfolio spanning cardiology, pain management, and other specialty areas similar to TriviumVet's focus.

Emerging players

• Aratana Therapeutics: Veterinary therapeutics company that developed first-in-class pet therapeutics for conditions including osteoarthritis pain and appetite stimulation. Acquired by Elanco in 2019. Highly comparable to TriviumVet's specialty vet pharma model targeting previously untreatable companion animal conditions.
• Nexvet Biopharma: Ireland-based veterinary biopharmaceutical company developing monoclonal antibody therapies for companion animals, acquired by Zoetis in 2017. Comparable to TriviumVet as a specialty vet biotech founded in Ireland, with focus on novel biologics for companion animal diseases.

Broad incumbents

• Phibro Animal Health: Diversified global animal health and nutrition company focused on livestock and companion animal health. Comparable to TriviumVet as an animal health pharmaceutical company, though Phibro has a much larger and broader portfolio spanning production animal health and nutrition.
• Elanco Animal Health: One of the largest global animal health companies, formed from Eli Lilly's animal health division and incorporating acquisitions including Aratana and Novartis Animal Health. Comparable as a broad incumbent with portfolio overlap in companion animal therapeutics including pain management and specialty categories.
• Zoetis: World's largest animal health company, spun off from Pfizer in 2013. Comparable to TriviumVet as the dominant specialty vet pharma incumbent with extensive companion animal therapeutic portfolio including cardiology, pain, and renal products, though operating at vastly larger scale.

Others

• Pegasus Laboratories (PRN Pharmacal): US-based veterinary pharmaceutical company specializing in specialty prescription products for companion animals, part of the PBI-Gordon group. Directly comparable to TriviumVet as a vet pharma distributor and commercial partner, with established US sales infrastructure for prescription veterinary products.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/triviumvet

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TriviumVet